Endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) play a critical role in immune-mediated demyelinating diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE), by regulating the viability of oligodendrocytes.
| I N TR ODU C TI ON
Endoplasmic reticulum (ER) stress activates the unfolded protein response (UPR), an adaptive response that is mediated by three ERresident transmembrane proteins: pancreatic ER kinase (PERK), inositol requiring enzyme 1 (IRE1), and activating transcription factor 6a (ATF6a) (Marciniak & Ron, 2006; Walter & Ron, 2011) . PERK activation inhibits global protein biosynthesis but stimulates certain cytoprotective gene expression by phosphorylating eukaryotic translation initiation factor 2a (eIF2a). IRE1 activation induces stress-responsive gene expression by splicing X-box binding protein 1(XBP1) mRNA.
ATF6a becomes active by transiting to the Golgi complex, where it is cleaved by the proteases S1P and S2P. Cleaved ATF6a translocates to the nucleus and functions as a transcription factor that enhances the expression of ER chaperones. The primary function of the UPR is to restore ER homeostasis and to adapt cells to stressful conditions. However, if the adaptive measures fail, the UPR triggers apoptosis programs to eliminate stressed cells (Tabas & Ron, 2011; Hetz, 2012) .
Each oligodendrocyte must produce enormous amounts of myelin proteins to assemble and maintain myelin sheath. It is known that oligodendrocytes are highly sensitive to disruption of ER homeostasis and that ER stress plays a critical role in various myelin disorders by regulating oligodendrocyte viability (Lin & Popko, 2009; pathway is not activated in oligodendrocytes under normal or disease conditions (Hussien et al., 2015; Stone & Lin, 2015) ; however, other studies show opposite results (Mh aille et al., 2008; Ní Fhlathartaigh et al., 2013; Naughton, McMahon, & FitzGerald, 2015) . A number of studies demonstrate that the PERK branch can positively or negatively influence oligodendrocyte viability in myelin disorders (Southwood, Garbern, Jiang, & Gow, 2002; Lin, Harding, Ron, & Popko, 2005; Lin et al., 2013 Lin et al., , 2014a Lin et al., , 2014b Hussien, Cavener, & Popko, 2014) . Nevertheless, despite observation of activation of the ATF6a branch in oligodendrocytes under normal and disease conditions (Mh aille et al., 2008; Naughton et al., 2015; Stone & Lin, 2015) , the effects of ATF6a activation on these cells remains unknown.
Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are immune-mediated demyelinating diseases of the CNS (Bauer, Rauschka, & Lassmann, 2001; Berard, Wolak, Fournier, & David, 2010; Kipp, Nyamoya, Hochstrasser, & Amor, 2017) . It is generally believed that MS and EAE are initiated by an autoimmune reaction against oligodendrocytes and myelin (Frohman, Racke, & Raine, 2006; Bradl & Lassmann, 2010) . A number of studies show that ER stress is a critical player in regulating oligodendrocyte viability in MS and EAE (Lin & Popko, 2009; Stone & Lin, 2015; Way & Popko, 2016) . Data from our laboratory and other groups demonstrate the cytoprotective effects of the PERK pathway on oligodendrocytes during EAE (Lin et al., 2013 (Lin et al., , 2014a Hussien et al, 2014) .
Moreover, we have generated a mouse model that allows for controllable expression of IFN-g, a key pro-inflammatory cytokine in MS and EAE, in the CNS (Lin et al., 2004) . Using the IFN-g-expressing mouse model, we and other groups demonstrate that the presence of IFN-g in the CNS of young, developing mice induces myelinating oligodendrocyte apoptosis through ER stress, and that activation of the PERK pathway protects myelinating oligodendrocytes against IFN-g-induced ER stress in the developing CNS (Lin et al., 2005 (Lin et al., , 2008 Lin & Lin, 2010; Lin et al., 2014a; Way et al., 2015) .
Data indicate that ATF6a activation promotes cell survival under stressful conditions (Egawa et al., 2011; Cao et al., 2013; Yoshikawa et al., 2015) . In this study, we sought to investigate the role of ATF6a in oligodendrocytes in immune-mediated demyelinating diseases using the IFN-g-expressing mouse model and the EAE model. We found that ATF6a deficiency increased the sensitivity of myelinating oligodendrocytes to IFN-g-induced ER stress in young, developing mice. We also found that ATF6a deficiency led to exacerbated oligodendrocyte death and increased disease severity in mice undergoing EAE. Our findings suggest that ATF6a deficiency increases the vulnerability of oligodendrocytes in immune-mediated demyelinating diseases.
| M A TE RI A L S A ND M E TH ODS

| Mice and EAE immunization
ATF6a heterozygous knock-out mice (Yamamoto et al., 2007) , GFAP/ tTA mice, and TRE/IFN-c mice (Lin et al., 2004) were on the C57BL/6J background. ATF6a heterozygous knock-out mice were intercrossed to get ATF6a homozygous knock-out (ATF6a KO) mice and control wild type (ATF6a WT) mice. GFAP/tTA mice and TRE/IFN-c mice were mated with ATF6a KO mice, and then the resulting progeny were intercrossed to obtain GFAP/tTA; TRE/IFN-c; ATF6a KO mice and GFAP/tTA; TRE/ IFN-c; ATF6a WT mice. 0.5 mg/ml doxycycline (Dox) was provided ad libitum in the drinking water from conception to repress the expression of the transgene IFN-g. Genotypes were determined by PCR from DNA extracted from tail tips as described in previous papers (Lin et al., 2004; Yamamoto et al., 2007) .
To induce EAE, 8-week-old female mice were injected subcutaneously in the flank and at the tail base with 200 lg of myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide emulsified in complete Freund's adjuvant (BD Biosciences, San Jose, CA) supplemented with 600 lg of Mycobacterium tuberculosis (strain H37Ra; BD Biosciences).
Two intraperitoneal injections of 400 ng pertussis toxin (List Biological
Laboratories, Denver, CO) were given 24 and 72 hr later. Clinical scores (0 5 healthy, 1 5 flaccid tail, 2 5 ataxia and/or paresis of hindlimbs, 3 5 paralysis of hindlimbs and/or paresis of forelimbs, 4 5 tetraparalysis, 5 5 moribund or death) were recorded daily (Lin et al., 2007 (Lin et al., , 2013 Stone et al., 2017) .
All animal procedures were conducted in complete compliance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Minnesota.
| Immunohistochemistry (IHC)
Anesthetized mice were perfused through the left cardiac ventricle with 4% paraformaldehyde in PBS. The tissues were removed, postfixed with paraformaldehyde, cryopreserved in 30% sucrose, embedded in optimal cutting temperature compound, and frozen on dry ice.
Frozen sections were cut using a cryostat at a thickness of 10 mm. The sections were treated with 2208C acetone, blocked with PBS containing 10% goat serum or horse serum and 0.1% Triton X-100, and incubated overnight with the primary antibody diluted in blocking solution. The intensity of BiP fluorescence in oligodendrocytes was measured as described previously (McCloy et al. 2014) . Briefly, the mean fluorescence of individual cells was quantified using the NIH ImageJ software (http://rsb.info.nih.gov/ij/; RRID:SCR_003070), several readings background fluorescent levels were also taken. The total corrected cellular fluorescence (TCCF) was determined using the formula TCCF 5 integrated density -(area of selected cell 3 mean fluorescence of background readings). BiP TCCF levels were normalized to the level of expression in the control mice.
For quantification of cells in EAE mice, we counted immunopositive cells within the anterior funiculus medially next to the anterior median fissure in the lumbar spinal cord, confined to an area of 0.1 mm 2 as described in our previous paper (Lin et al., 2007 (Lin et al., , 2013 (Lin et al., , 2014a . For quantitative MBP IHC analysis in EAE mice, we calculated the percentage of the demyelinated area in the lumbar spinal cord by normalizing the demyelinated area against the total white matter area.
The total white matter area and the demyelinated area in the lumbar spinal cord were measured by NIH ImageJ software as described in our previous paper (Lin et al., 2007 (Lin et al., , 2013 .
| Toluidine blue staining and electron microscopy (EM) analysis
Mice were anaesthetized and perfused with PBS containing 4% paraformaldehyde and 2.5% glutaraldehyde. The lumbar spinal cord and corpus callosum were processed and embedded. For EAE mice, 1 lm sections were cut, stained with toluidine blue, and analyzed as previously described (Lin et al., 2007 (Lin et al., , 2013 . The total white matter area and the demyelinated area in the lumbar spinal cord were measured with the NIH ImageJ software. The percentage of the demyelinated area was calculated by normalizing the demyelinated area against the total white matter area. For EM analysis, ultrathin sections were cut, stained with uranyl acetate and lead citrate, and analyzed as described previously (Lin, et al., 2005 (Lin, et al., , 2014a (Lin, et al., , 2014b Stone et al., 2017) . We counted the total number of axons, the number of myelinated axons, and calculated the percentage of myelinated axons. The diameter of axons and the thickness of myelin sheaths were measured.
| Real-time PCR and XBP1 splicing assay
Deeply anesthetized mice were perfused with ice-cold PBS and the spinal cords were extracted and snap frozen with dry ice. RNA was isolated from the whole spinal cord using Trizol reagent (Invitrogen, Carlsbad, CA) and treated with DNaseI (Invitrogen) to eliminate genomic DNA. Reverse transcription was performed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). TaqMan realtime PCR was performed with iQ Supermix (Bio-Rad Laboratories) on the LightCycler 480 System (Roche Diagnostics Corporation, Indianapolis, IN) as described in our previous papers (Lin et al., 2005 (Lin et al., , 2007 (Lin et al., , 2013 . PCR for XBP1 was performed to detect spliced XBP1 (XBP1s)
using Taq DNA Polymerase (Qiagen, Germantown, MD). PCR products were separated by electrophoresis on a 3% agarose gel. Mice heterozygous for Patched1 (Ptch11/2) with medulloblastoma (MB) were used as a positive control for XBP1 splicing Stone et al. 2016 ).
| Western blot analysis
Whole spinal cords harvested from mice were rinsed in ice-cold PBS and were homogenized using a motorized homogenizer as previously described (Lin et al., 2005 (Lin et al., , 2013 AB_2336177; anti-rabbit, RIDD:AB_2336198), and, following incubation with the ECL Detection Reagents (GE Healthcare Biosciences, Pittsburgh, PA), the chemiluminescent signal was detected. The intensity of the recorded chemiluminescence signals of CHOP and actin was quantified using the NIH ImageJ software.
| T-cell proliferation assay and cytokine assay
Spleen leukocytes were generated from EAE mice at postimmunization day (PID) 10 and plated in 96-well microtiter plates as previously described (Lin et al., 2013; Stone et al., 2017) . The cells were treated with MOG 35-55 peptide (0, 1, 10, or 100 mg/ml), and were incubated at 378C and 5% CO 2 . After 48 hr, 20 ml of BrdU labeling solution (Millipore) was added to the culture media for 24 hr. Cell proliferation was determined using the Colorimetric BrdU Cell Proliferation kit (Millipore) according to manufacturer's instructions. We quantified the cytokines in the culture supernatants using the ELISA kits (IFN-g, IL-4, Thermo Scientific, Grand Island, NY; IL-17A, BioLegend, San Diego, CA) according to the manufacturer's instructions.
| Flow cytometry analysis
Deeply anesthetized mice were perfused with 50 ml 0.9% NaCl solution. Whole spinal cord was harvested and single cell suspensions were generated by passing tissues through a 70 mm cell strainer. Spinal cord cell suspensions were centrifuged in a 70%: 30% discontinuous Percoll CA) and the Flowing Software version 2.5.1 (Perttu Terho, Turku Centre for Biotechnology, Finland) as previously described (Fife et al., 2001 ).
| Experimental design and statistical analysis
For EAE experiments only female mice were used due to the wellknown sex differences in the EAE model (Voskuhl & Palaszynski, 2001; Rahn, Iannitti, Donahue, & Taylor, 2014; Zhu et al., 2016) . EAE clinical score data is presented as mean 6 SEM and compared using a two way ANOVA with a Sidak's multiple comparisons test using GraphPad Prism 6 (GraphPad Software, RRID:SCR_002798). All other data are expressed as mean 6 SD. Comparison between two groups was statistically evaluated by t test using GraphPad Prism 6. Multiple comparisons were statistically evaluated by the 1-way ANOVA with a Tukeys posttest using GraphPad Prism 6. Phenotypic differences among the groups were statistically evaluated by the v 2 -test using GraphPad Prism 6. p values <.05 were considered significant.
| R E SU LTS
| ATF6a deficiency did not affect oligodendrocyte viability or function under physiological conditions
ATF6a functions as the master regulator of ER chaperone expression during ER stress (Marciniak & Ron, 2006; Walter & Ron, 2011) . Recent studies show that mutations of ATF6a cause the cone dysfunction disorder achromatopsia in human patients (Kohl et al., 2015; Ansar et al., 2015) . ATF6a KO mice appear healthy and exhibit normal retinal morphology and function at a young age; however, aged mice display rod and cone dysfunction (Yamamoto et al., 2007; Kohl et al., 2015) . A report shows that ATF6a is activated in oligodendrocytes in young, developing mice and adult mice (Naughton et al., 2015) . Moreover, a study shows that deletion of BiP, an ER chaperone and ATF6a-responsive gene, specifically in oligodendrocytes leads to oligodendrocyte death and myelin loss in both young, developing mice and adult mice (Hussien et al., 2015) . Thus, we determined the potential role of ATF6a in oligodendrocytes under physiological conditions. IHC for CC1, a marker for oligodendrocytes, showed that the number of oligodendrocytes in the CNS of 21-day-old ATF6a KO mice was comparable 
| ATF6a deficiency rendered myelinating oligodendrocytes susceptible to IFN-c
Ectopic expression of IFN-g in the developing CNS stimulates inflammation, including T-cell infiltration, microglia/macrophage activation, and upregulation of inflammatory mediators, and leads to myelinating oligodendrocyte death and myelin loss, which recapitulates multiple pathological features of MS demyelinating lesions (Corbin et al., 1996; LaFerla, Sugarman, Lane, & Leissring, 2000; Lin & Lin, 2010; Lin et al., 2014a) . Importantly, we demonstrate that the presence of IFN-g in the developing CNS induces myelinating oligodendrocyte apoptosis through ER stress (Lin et al., 2005 (Lin et al., , 2008 Lin & Lin, 2010) . Moreover, we show that PERK inactivation makes myelinating oligodendrocytes vulnerable to IFN-g, and that enhanced PERK activation renders myelinating oligodendrocytes resistant to IFN-g (Lin et al., 2005 (Lin et al., , 2014a . It is known that ATF6a activation protects cells against ER stress (Marciniak & Ron, 2006; Walter & Ron, 2011) . Therefore, we determined the effects of ATF6a deficiency on ER-stressed oligodendrocytes in IFN-g-expressing mice.
We have generated a mouse model that allows for controllable expression of IFN-g in the CNS using the tetracycline inducible system (Lin et al., 2004) . KO mice were released from Dox at E14 (IFN-g1; ATF6a KO mice).
Another group of GFAP/tTA; TRE/IFN-c; ATF6a KO mice never released from Dox served as controls (IFN-g-; ATF6a KO mice). Consistent with previous reports (Lin et al., 2005 (Lin et al., , 2008 (Lin et al., , 2014a , we found that a number of IFN-g1; ATF6a WT mice exhibited tremor and ataxia. Interestingly, the tremoring phenotype displayed by IFN-g1; ATF6a KO mice was significantly more severe than IFN-g1; ATF6a WT mice (Table 1) .
Despite considerable efforts, we could not find a reliable antiATF6a antibody for IHC. In contrast, it is well documented that the chaperone BiP is an ATF6a-responsive gene in ER-stressed cells. Thus, we used CC1 and BiP double immunostaining to gauge the activity of ATF6a signaling in oligodendrocytes in these four groups of mice. As Evidence suggests that ATF6a deficiency may suppress inflammation (Rao et al., 2014; Ta et al., 2016) . We further determined whether ATF6a deficiency affects inflammation in the CNS of IFN-g-expressing mice. CD11b IHC showed that microglia in both IFN-g-; ATF6a WT mice and IFN-g-; ATF6a KO displayed a typical ramified morphology.
Interestingly, microglia/macrophages were strongly activated in the CNS of IFN-g1; ATF6a WT mice compared with the control IFN-g-;
ATF6a WT mice and IFN-g-; ATF6a KO mice; however, ATF6a defi- | 1335 Way & Popko, 2016) . Enhanced PERK activation in oligodendrocytes attenuates EAE severity and ameliorates EAE-induced oligodendrocyte death and demyelination (Lin et al., 2013) . In contrast, PERK inactivation in oligodendrocytes increases EAE severity and enhances EAE-induced oligodendrocyte death and demyelination (Hussien et al., 2014) . We assessed the effects of ATF6a deficiency on oligodendrocytes during EAE. ATF6a WT mice and ATF6a KO mice were immunized with MOG35-55 peptide to induce EAE. ATF6a WT mice displayed a typical EAE disease course, disease onset around PID12 and reaching the peak severity around PID19 (Figure 5a,b) . Interestingly, ATF6a KO mice developed significantly more severe EAE clinical symptoms compared with ATF6a WT mice (Figure 5a,b) . Moreover, ATF6a KO mice exhibited a very high rate of mortality (9 out of 21 ATF6a KO mice vs.
1 out of 15 ATF6a WT mice, Figure 5b ).
Western blot analysis showed that the cleaved ATF6a was undetectable in the spinal cord of naïve ATF6a WT mice, but was clearly present in the spinal cord of ATF6a WT mice with EAE ( Figure 5c ). As and ATF6a KO mice, CNS tissues were prepared from these EAE mice at PID19 when ATF6a WT mice were at the peak of disease. Finally, we determined whether ATF6a deficiency affects the activation of the IRE1 and PERK branches in the CNS of mice undergoing EAE. The PCR-based assays that examine XBP1 splicing are highly sensitive methods for detection of activation of the IRE1-XBP1 pathway (Cox et al., 2011) . We found that spliced XBP-1 was undetectable in the spinal cord of either naïve ATF6a WT mice or ATF6a WT mice with EAE, but became detectable in ATF6a KO mice with EAE (Supporting Information Figure S2a ). These results suggest that ATF6a deficiency exacerbates ER stress in CNS cells during EAE, resulting in activation of the IRE1-XBP1 pathway in these cells. Moreover, it is known that induction of CHOP is dependent on activation of the PERK-eIF2a pathway in ER-stressed cells (Marciniak & Ron, 2006; Lin et al., 2013 Lin et al., , 2014a Lin et al., , 2014b . Western blot analysis showed that the level of CHOP was significantly increased in the spinal cord of ATF6a WT mice with EAE compared with naïve ATF6a WT mice, and that CHOP level was significantly decreased in the spinal cord of ATF6a KO mice with EAE compared with ATF6a WT mice with EAE (Supporting Information Figure S2b,c) . Previous studies have demonstrated activation of the PERK-eIF2a pathway in oligodendrocytes during EAE (Lin et al., 2007 (Lin et al., , 2013 Hussien et al., 2014) . We showed here that ATF6a deficiency exacerbated oligodendrocyte loss during EAE. Thus, these data raise the possibility that exacerbation of oligodendrocyte loss contributes to the decreased level of CHOP in the spinal cord of ATF6a KO mice with EAE.
| D ISC USSION
It is well documented that ER stress plays a critical role in various myelin disorders by regulating oligodendrocyte viability (Lin & Popko, 2009; Clayton & Popko, 2016; Volpi et al., 2017) . MS and EAE are believed to be initiated by an autoimmune reaction against oligodendrocytes and myelin (Frohman et al., 2006; Bradl & Lassmann, 2010; Kipp et al., 2017) . Recent studies show that ER stress modulates oligodendrocyte viability during EAE, and subsequently influences the disease development (Lin et al., 2007 (Lin et al., , 2013 Hussien et al., 2014) . Importantly, several studies demonstrate that activation of the PERK pathway in oligodendrocytes is cytoprotective, protecting mice against EAE (Lin et al., 2013; Hussien et al., 2014) . Nevertheless, the effects of the ATF6a pathway on oligodendrocytes in MS and EAE remain unknown.
To explore the effects of ATF6a on oligodendrocytes in immunemediated demyelinating diseases, we first used a mouse model that Results presented as mean 6 SD. N 5 3 animals. n.s. Not significant. (Corbin et al., 1996; LaFerla et al., 2000; Lin & Lin, 2010; Lin et al., 2014a) . Importantly, it has been demonstrated that IFN-g induces myelinating oligodendrocyte death through ER stress (Lin et al., 2005 (Lin et al., , 2008 Lin & Lin, 2010) . Our previous studies show that decreased PERK activation exacerbates ER stress-induced myelinating oligodendrocyte death in the developing CNS of IFN-g-expressing mice, and that enhanced PERK activation protects myelinating oligodendrocytes against IFN-g-induced ER stress in the developing CNS (Lin et al., 2005 (Lin et al., , 2008 (Lin et al., , 2014a . We showed here that ATF6a deficiency eliminated IFN-g-induced ATFa activation in oligodendrocytes and exacerbated IFN-g-induced myelinating oligodendrocyte death and myelin loss in the developing CNS. Moreover, we found that ATF6a deficiency did not alter inflammation in the CNS of IFN-g-expressing mice. The cytoprotective role of ATF6a activation in ER-stressed cells is well documented (Marciniak & Ron, 2006; Walter & Ron, 2011) . Thus, these data suggest that ATF6a deficiency renders myelinating oligodendrocytes sensitive to IFN-g-induced ER stress in the developing CNS.
FIG URE
We further explored the effects of ATF6a on oligodendrocytes in immune-mediated demyelinating diseases using the EAE model. Recent studies show that ER stress is a critical player in regulating oligodendrocyte viability during EAE (Lin & Popko, 2009; Stone & Lin, 2015; Way & Popko, 2016) . Several studies show that PERK activation protects oligodendrocytes against inflammation during EAE, and results in attenuated EAE severity (Lin et al., 2013; Way et al., 2015) . In contrast, a report shows that PERK inactivation facilitates oligodendrocyte death during EAE, and leads to exacerbated EAE severity (Hussien et al, 2014) . We showed here that ATF6a deficiency abrogated ATF6a activation in oligodendrocytes, increased disease severity, and exacerbated oligodendrocyte death and demyelination in EAE mice. We also showed that ATF6a deficiency had no significant effect on T-cell priming in the peripheral immune system and on inflammation in the CNS during EAE. Although data indicate that the UPR influences innate and adaptive immune responses, there is no evidence that ATF6a deficiency enhances the activity of inflammatory cells (Garg et al., 2012; Janssens, Pulendran, & Lambrecht, 2014; Rao et al., 2014; Ta et al., 2016) . Collectively, these data suggest that ATF6a deficiency renders oligodendrocytes vulnerable to inflammation during EAE, resulting in exacerbated EAE severity.
During EAE pathogenesis, inflammation causes oligodendrocyte death and demyelination, and then oligodendrocyte death and demyelination promote inflammation, forming a vicious circle (Frohman et al., 2006; Bradl & Lassmann, 2010; Kipp et al., 2017) . While we showed that there was no significant difference in inflammatory cell infiltration in the CNS of ATF6a KO mice and ATF6a WT mice, flow cytometry analysis showed a trend of decreased inflammatory cell infiltration in the whole spinal cord of ATF6a KO mice with EAE. In contrast, IHC analysis showed a trend of increased inflammatory cell infiltration in the demyelinating lesions in the lumbar spinal cord of ATF6a KO mice with EAE. Several lines of evidence suggest that increased oligodendrocyte death and demyelination can lead to enhanced inflammation in the demyelinating lesions during EAE (Hisahara et al., 2000 (Hisahara et al., , 2001 Mc Guire et al., 2010) . Moreover, recent reports suggest that ATF6a inactivation can reduce the activity of microglia or macrophages (Rao et al., 2014; Ta et al., 2016) . Thus, these data raise the possibilities that: (1) ATF6a deficiency in inflammatory cells moderately suppress inflammation, resulting in a trend of decreased inflammatory cell infiltration in the whole spinal cord during EAE; (2) exacerbated oligodendrocyte death and demyelination induced by ATF6a deficiency in oligodendrocytes attract inflammatory cells and concentrate them in active EAE lesions, resulting in a trend of increased inflammatory cell infiltration in the lesion sites. Clearly, the precise role of ATF6a inactivation in individual cell types, including oligodendrocytes, T cells, microglia, macrophages, or astrocytes, during EAE warrants a further investigation.
Unfortunately, the ATF6a KO mice used in this study do not allow us to dissect the cell-automatous role of ATF6a in these individual cell types in EAE mice. Cell-specific conditional ATF6a KO mouse models are required for addressing this important question. Regardless, establishment of the inhibitory effects of ATF6a deficiency on inflammatory cells in EAE mice will not compromise the conclusion drawn from this study, namely that ATF6a deficiency renders oligodendrocytes vulnerable to inflammation. Rather, it will provide additional evidence supporting the conclusion.
Interestingly, consistent with our observation regarding the potentially inhibitory effects of ATF6a deficiency on inflammatory cells, a recent report shows that ATF6a deficiency moderately but significantly inhibits cultured microglial activation in response to lipopolysaccharide (LPS; Ta et al., 2016) . Nevertheless, in contrast to our study, Ta et al.
show that ATF6a deficiency decreases EAE severity, although the report also shows that ATF6a deficiency does not affect T-cell priming during EAE (Ta et al., 2016) . Notably, Ta peptide 1 400 ng pertussis toxin used in this study) to induce EAE in male mice on the C57BL/6 background (vs. female mice on the C57BL/6J background used in this study). Sex difference in both MS patients and EAE animals is well known (Voskuhl & Palaszynski, 2001; Rahn et al., 2014; Zhu et al., 2016) . Therefore, the discrepancy of EAE severity between these two studies likely reflects that the immunization regimen used by Ta et al. is not strong enough to induce sufficient inflammation to kill oligodendrocytes in male ATF6a KO mice at the initiation stage of EAE, so that the contribution of ATF6a deficiency in oligodendrocytes to EAE development cannot be realized. In contrast, the immunization regimen used in this study is strong enough to induce full blown EAE in female ATF6a KO mice, despite a potentially, moderately anti-inflammatory effect of ATF6a deficiency. The detrimental effects of ATF6a deficiency on oligodendrocytes outweigh the moderately anti-inflammatory effects of ATF6a deficiency on inflammatory cells, resulting in increased EAE severity.
ATF6a functions as the master regulator of ER chaperone expression during ER stress (Yamamoto et al., 2007; Walter & Ron, 2011) .
Data suggest that ATF6a deficiency diminishes induction of ER chaperones during ER stress, and results in increased cell apoptosis (Cao et al., 2013) . A report shows that BiP is required for oligodendrocyte survival under normal condition and that heterozygous deficiency of BiP specifically in oligodendrocytes increases EAE disease severity and exacerbates EAE-induced oligodendrocyte death and demyelination (Hussien et al., 2015) . We showed here that ATF6a deficiency diminished BiP induction in oligodendrocytes and enhanced oligodendrocyte death in the CNS of IFN-g-expressing mice and EAE mice. Thus, it is possible that ATF6a deficiency increases the vulnerability of oligodendrocytes in immune-mediated demyelinating diseases by attenuating induction of BiP.
In summary, using the IFN-g-expressing mouse model, we showed that ATF6a deficiency renders myelinating oligodendrocytes sensitive to IFN-g-induced ER stress in the developing CNS. Moreover, using the EAE model, we showed that ATF6a deficiency renders oligodendrocytes vulnerable to inflammation during EAE. The results presented in this study suggest that ATF6a deficiency increases the vulnerability of oligodendrocytes in immune-mediated demyelinating diseases, implying the cytoprotective effects of ATF6a activation on oligodendrocytes in MS. Importantly, in contrast to the PERK pathway that functions as a double-edged sword during ER stress, there is no evidence that ATF6a activation triggers apoptosis programs in ERstressed cells (Tabas & Ron, 2011; Hetz, 2012 
